Panbela Therapeutics Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company, is proud to announce a poster presentation that will be featured at the American Association for Cancer Research (AACR) this April.
The presentation will highlight the results of ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer, which is the product of a successful collaboration between Panbela Therapeutics and Johns Hopkins University School of Medicine. This work is part of the company’s ongoing mission to develop revolutionary therapeutics for patients with urgent unmet medical needs.
Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela, is excited to share the news that the treatment of C57Bl/6 mice injected with VDID8+ ovarian cancer with SBP-101 in combination with chemotherapy has been observed to dramatically prolong survival and reduce overall tumor burden.
This groundbreaking research is part of an ongoing collaboration with Johns Hopkins University School of Medicine, and paves the way for Panbela’s plans to launch its ovarian cancer program this year.
The results of Dr. Simpson’s study suggest that the combination of the drug SBP-101 and doxorubicin may be a beneficial treatment option for ovarian cancer, particularly in the platinum-resistant patient population where few options exist.
This research sets the groundwork for clinical trials to further explore the potential of SBP-101 in combination with doxorubicin as a way to provide effective treatments for those with unmet medical needs.
A revolutionary breakthrough in the fight against ovarian cancer is here! SBP-101, when combined with the standard of care chemotherapy agents gemcitabine, topotecan, and doxorubicin, has been proven to have a significant increase in toxicity in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines.
Paclitaxel and docetaxel, however, have not been shown to add any further benefit when SBP-101 is used alone. Join the fight against ovarian cancer and make SBP-101 your weapon of choice!
The VDID8+ murine ovarian cancer model proved the efficacy of SBP-101 when combined with gemcitabine, topotecan, or doxorubicin. While gemcitabine and topotecan alone had little effect on mouse survival time, when combined with SBP-101, the results were far more impressive. SBP-101 in combination with doxorubicin even increased the median mouse survival time by an impressive 265% compared to untreated animals. Clearly, SBP-101 is a powerful tool in the fight against ovarian cancer.
The combination of DFMO and ivospemin has been found to have a cooperative antiproliferative response in vitro, suggesting potential therapeutic benefits. DFMO is well-tolerated and has the potential to modulate the immune cells in the tumor microenvironment, thereby promoting a more immune-friendly environment. Future experiments will assess the efficacy of combining DFMO with ivospemin and its influence on the immune cells in the tumor microenvironment.
The exciting results of the study on C57Bl/6 mice with VDID8+ ovarian cancer demonstrate that treatment with SBP-101 in combination with doxorubicin significantly extended survival and reduced tumor burden. These findings open up new possibilities for further research into the effects of SBP-101 combined with other polyamine metabolism modulators and immune modulators.
About Panbela’s Pipeline
Our pipeline is packed with cutting-edge clinical trials, with an initial focus on treating and preventing some of the most serious forms of cancer. We have projects underway that target familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer. Our development plans have plenty of exciting milestones in store, from pre-clinical research all the way through to registration studies.
Ivospemin, an innovative polyamine analogue, has demonstrated its potential as a tumor growth inhibitor in clinical studies involving metastatic pancreatic cancer patients. The median overall survival (OS) rate was 14.6 months, and the objective response rate (ORR) was 48%, both of which exceeded the typical standard of care of gemcitabine + nab-paclitaxel.
Additionally, ivospemin has not been associated with worsened bone marrow suppression or peripheral neuropathy, which can be side effects of chemotherapy. Furthermore, visual adverse events have been evaluated to ensure patient safety, and those with a history of retinopathy or at risk of retinal detachment are excluded from future SBP-101 studies.
The promising safety data and PMI profile observed in the Panbela-sponsored clinical trials provide further evidence to support the continued evaluation of ivospemin in the ASPIRE trial.
Flynpovi, a combination of CPP-1X (eflornithine) and sulindac, has demonstrated remarkable efficacy in a Phase 3 clinical trial for preventing pre-cancerous adenomas in patients with sporadic large bowel polyps.
Most recently, Flynpovi has also been evaluated in a Phase 3 trial for FAP patients with lower gastrointestinal tract anatomy and has shown statistically significant benefit compared to single agents in delaying surgical events for up to four years. What’s more, the safety profile of Flynpovi was no different from that of the single agents, providing further evidence of its potential value in treating FAP.
CPP-1X (eflornithine) is revolutionizing the way we think about prevention and treatment. Preclinical and clinical trials have already begun to reveal its potential in preventing gastric cancer, treating neuroblastoma, and even managing the onset of Type 1 diabetes. With a well-tolerated single agent tablet or high dose powder sachet, CPP-1X is becoming an increasingly sought-after treatment option.
Panbela Therapeutics, Inc. is a pioneering biopharmaceutical company striving to revolutionize the treatment of urgent and unmet medical needs. As its flagship products, Ivospemin (SBP-101) and Flynpovi are currently undergoing clinical trials, providing hope to many patients who had previously had limited treatment options.